Complete reference guide to regulatory terms, acronyms, and definitions used by FDA, EMA, and Health Canada. Essential resource for regulatory affairs professionals.
FDA division responsible for evaluating small molecule drugs before they can be sold in the United States. Ensures drugs are safe and effective.
FDA division responsible for regulating biologics including vaccines, blood products, cellular therapies, gene therapies, and allergenics.
FDA division responsible for medical devices and radiation-emitting products, including diagnostics and imaging equipment.
FDA office that oversees pharmaceutical manufacturing compliance, conducts inspections, and issues warning letters.
FDA office focused on dietary supplements, ensuring safety and proper labeling.
Application required before testing a new drug in human clinical trials. Must include preclinical data, manufacturing information, and clinical trial protocols.
Application to FDA requesting approval to market a new drug in the United States. Includes all clinical trial data, manufacturing details, and labeling.
Application required to market a biologic product in the United States. Similar to NDA but for biologics like vaccines and gene therapies.
Application for approval of a generic drug. Requires demonstration of bioequivalence to the reference listed drug.
Medical device application demonstrating substantial equivalence to a legally marketed predicate device.
European Union agency responsible for evaluating and supervising medicinal products for human and veterinary use.
EMA scientific committee responsible for preparing opinions on marketing authorization applications for human medicines.
European equivalent of FDA NDA. Application to obtain approval to market a medicine in the EU.
European marketing authorization procedure that results in approval valid across all EU member states simultaneously.
EMA committee responsible for safety monitoring of medicines throughout their lifecycle.
Initial clinical trials testing safety, dosage range, and side effects in small groups (20-100 healthy volunteers or patients).
Clinical trials evaluating drug efficacy and further safety in larger patient populations (100-300 patients with the condition).
Large-scale trials (300-3,000+ patients) confirming drug effectiveness, monitoring side effects, and comparing to standard treatments.
Studies conducted after drug approval to monitor long-term safety, effectiveness in broader populations, and identify rare adverse events.
FDA-required safety program for drugs with serious safety concerns, ensuring benefits outweigh risks.
Any undesirable medical occurrence in a patient administered a pharmaceutical product, regardless of causality.
Adverse event that results in death, hospitalization, disability, birth defects, or requires intervention to prevent permanent impairment.
Periodic pharmacovigilance document providing evaluation of risk-benefit balance of a medicine.
FDA database containing information on adverse event and medication error reports submitted for approved drugs and biologics.
Quality assurance system ensuring pharmaceuticals are consistently produced and controlled according to quality standards.
Updated GMP regulations incorporating current technology and systems for pharmaceutical manufacturing.
FDA inspection of manufacturing facility before approving a new drug application to verify GMP compliance.
Official correspondence from FDA notifying of regulatory violations that may result in enforcement action if not corrected.
Document issued by FDA at conclusion of facility inspection listing observed conditions that may constitute violations.
FDA program expediting development and review of drugs treating serious conditions and addressing unmet medical needs.
FDA designation for drugs showing substantial improvement over existing therapies for serious or life-threatening diseases.
FDA review designation reducing review time to 6 months instead of standard 10 months for drugs offering significant improvements.
FDA pathway allowing approval based on surrogate endpoints for drugs treating serious conditions with unmet medical needs.
Designation for drugs treating rare diseases (affecting fewer than 200,000 US patients), providing development incentives.
Federal department responsible for helping Canadians maintain and improve health, regulating pharmaceuticals and medical devices.
Computer-generated eight-digit number assigned by Health Canada to approved drug products for sale in Canada.
Health Canada authorization to market a new drug product, confirming it meets safety, efficacy, and quality standards.
Submission to Health Canada for changes to approved drugs, including formulation, indication, or manufacturing changes.
FDA, EMA, or Health Canada document providing recommendations on regulatory topics but not legally enforceable.
Preliminary guidance document released for public comment before finalization.
Global regulatory guideline harmonizing technical requirements for pharmaceutical product registration.
Official FDA letter granting permission to market a drug, including approved labeling and conditions.
FDA letter indicating application review cycle is complete but additional information is needed before approval.
Get automated regulatory updates with intelligent summaries delivered to your inbox daily.
Start Free 14-Day Trial